Adult-Onset Still Disease Market Analysis

Adult Onset Still disease (AOSD) is a rare inflammatory arthritis that mainly starts in adulthood and affects the entire body. The symptoms, progression and severity of the disease vary significantly from person to person.

Some of the most common symptoms of Adult-Onset Still's Disease includes a daily fever, sore throat, salmon-pink rash, achy and swollen joints (especially knees and wrists), muscular pain, abdominal pain, inflamed or swollen lymph nodes, and other symptoms that are associated with systemic inflammatory disease.

It is observed that Adult onset Still’s disease affects men and women in equal numbers. Adult-Onset Still's Disease mainly affects young adults aged between 16-35. Due to highly variable symptoms the disease remains undiagnosed or misdiagnosed.

Some of the key companies involved in developing therapies for Adult-Onset Still Disease include Novartis Pharmaceuticals, AB2 Bio, Hikma Pharmaceuticals, Teva Pharmaceutical, Swedish Orphan Biovitrum, Jubilant Life Sciences, Mylan N.V., and many others.

For more details on Adult-Onset Still Disease Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/adult-onset-still-disease-market